<SEC-DOCUMENT>0001193125-25-142093.txt : 20250617
<SEC-HEADER>0001193125-25-142093.hdr.sgml : 20250617
<ACCEPTANCE-DATETIME>20250617162517
ACCESSION NUMBER:		0001193125-25-142093
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250617
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250617
DATE AS OF CHANGE:		20250617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001095981
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				330827593
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34375
		FILM NUMBER:		251053636

	BUSINESS ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756
		BUSINESS PHONE:		737.255.7194

	MAIL ADDRESS:	
		STREET 1:		4200 MARATHON BLVD.
		STREET 2:		SUITE 200
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78756

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTORI THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050712

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MACROPORE INC
		DATE OF NAME CHANGE:	20010320
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d942989d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pstv="http://www.plustherapeutics.com/20250617" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-06-17_to_2025-06-17">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-278">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-06-17_to_2025-06-17">0001095981</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="pstv-20250617.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-06-17_to_2025-06-17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001095981</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-06-17</xbrli:startDate> <xbrli:endDate>2025-06-17</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-289">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt:datemonthdayyearen" id="ixv-290">June&#160;17, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-291">PLUS THERAPEUTICS, INC.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:stateprovnameen" id="ixv-292">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-293">001-34375</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-294">33-0827593</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-295">2710 Reed Road</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-296">Suite 160</ix:nonNumeric>,</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-297">Houston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:stateprovnameen" id="ixv-298">Texas</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-299">77051</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, with zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-300">(737)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-301">255-7194</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-303">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-306">Common Stock, par value $0.001</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-307">PSTV</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Capital Market</span> </td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-06-17_to_2025-06-17" format="ixt-sec:boolballotbox" id="ixv-308">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, on March&#160;4, 2025, Plus Therapeutics, Inc. (the &#8220;Company&#8221;) entered into that certain Securities Purchase Agreement, dated March&#160;4, 2025 (the &#8220;Purchase Agreement&#8221;), with the various purchasers party thereto (the &#8220;Purchasers&#8221;), pursuant to which the Company issued to such Purchasers in an private placement (the &#8220;March 2025 Private Placement&#8221;) the following securities of the Company: (i)&#160;an aggregate of 4,069,738 shares (the &#8220;Private Placement Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), (ii)&#160;prefunded warrants (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) to purchase an aggregate of up to 23,972,400 shares of Common Stock (the &#8220;Prefunded Warrant Shares&#8221;), (iii) Series A Warrants (the &#8220;Series A Warrants&#8221;) to purchase up to an aggregate of 280,421,380 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series A Warrants) (the &#8220;Series A Warrant Shares&#8221;), and (iv)&#160;Series B Warrants (the &#8220;Series B Warrants&#8221;) to purchase up to an aggregate of 1,261,896,210 shares of Common Stock (assuming full adjustment based on the floor price specified in the Series B Warrants and accounting for the alternative cashless exercise feature of 3:1 contained therein) (the &#8220;Series B Warrant Shares&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&#160;17, 2025, the Company and the Purchasers entered into a letter agreement (the &#8220;Letter Agreement&#8221;) with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement. Pursuant to the Letter Agreement: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Cancellation of Series </span><span style="font-style:italic">A</span><span style="font-style:italic"> Warrants</span>. The Company and each of the Purchasers agreed to terminate all Series A Warrants in full. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Amendment of Series B Warrants</span>. The Company and each of the Purchasers agreed to amend all outstanding Series B Warrants in the form of Exhibit 4.1 hereto (the &#8220;Amended Series B Warrants&#8221;) to (a)&#160;reduce the overall number of Series B Warrant Shares issuable upon exercise of the Series B Warrants to an aggregate of up to 35,536,380 Series B Warrant Shares, (b)&#160;reduce the alternative cashless exercise ratio in such Series B Warrants from 3:1 to 1:1, and (c)&#160;remove provisions contained in the Series B Warrants that would otherwise reduce the Company&#8217;s stockholders&#8217; equity. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Waiver of Registration Rights Agreement</span>. The Company and each of the Purchasers agreed to terminate the Registration Rights Agreement and nullify all past, present and future obligations with respect thereto. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Return of Private Placement Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants</span>. Each of the Purchasers agreed to return an aggregate of 12,241,986 Private Placement Shares and <span style="white-space:nowrap">Pre-Funded</span> Warrants issuable for an aggregate of 10,633,650 <span style="white-space:nowrap">Pre-Funded</span> Warrant Shares, held by them as of the date of the Letter Agreement, upon request of the Company, which were issued pursuant to the Purchase Agreement for a value of $0.66 per Private Placement Share and $0.659 per <span style="white-space:nowrap">Pre-Funded</span> Warrant. In exchange therefore, the Company agreed to repay the Purchasers holding such securities 115% of such value, using 90% of the proceeds from any capital raised by the Company subsequent to July&#160;1, 2025. The Company and each of the Purchasers also agreed to waive any restrictions on subsequent equity sales and variable rate transactions contained in Purchase Agreement to allow for such repayment. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of the&#160;Letter Agreements and A&amp;R Series B Warrants are qualified in their entirety by reference to the full text of such documents, copies of which are attached hereto as exhibits, and each of which is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;3.03</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Material Modification to Rights of Security Holders. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent required, the information contained in Item 1.01 above is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942989dex41.htm">Form of A&amp;R Series B Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d942989dex101.htm">Form of Letter Agreement. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: June&#160;17, 2025 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border-spacing:0">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">PLUS THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc H. Hedrick, M.D.</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Marc H. Hedrick, M.D.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d942989dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS
SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF AMENDED AND RESTATED SERIES B COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PLUS THERAPEUTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: [&#9679;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issuance Date: March&nbsp;4, 2025</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS WARRANT TO PURCHASE COMMON STOCK</B> (the &#147;<B><U>Warrant</U></B>&#148;) certifies that, for value
received, [&#149;] or its assigns (the &#147;<B><U>Holder</U></B>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date and on or
prior to 5:00 p.m. (New York City time) on the thirty (30)&nbsp;month anniversary of the Initial Exercise Date (the &#147;<B><U>Termination Date</U></B>&#148;) but not thereafter, to subscribe for and purchase from Plus Therapeutics, Inc., a
Delaware corporation (the &#147;<B><U>Company</U></B>&#148;), up to [&#149;] shares (as subject to adjustment hereunder, the &#147;<B><U>Warrant Shares</U></B>&#148;) of Common Stock. Subject to the provisions of Section&nbsp;2.3, the purchase price
of one (1)&nbsp;share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2.2. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Definitions</U></B>. In addition to the terms defined elsewhere in this Warrant or in the Purchase
Agreement, the following terms have the meanings indicated in this Section&nbsp;1. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Affiliate</U></B>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls
or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Bid Price</U></B>&#148; means, for any date, the price determined by the first of the following clauses that
applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted
as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Board of Directors</U></B>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Business Day</U></B>&#148; means a Calendar Day other than a Saturday, Sunday or any other Calendar Day which is a
federal legal holiday in the United States or any Calendar Day on which the commercial banks in the City of New York are required by law or other governmental action to close, provided that the commercial banks in the City of New York shall not be
deemed to be required to be closed due to a &#147;stay at home,&#148; &#147;shelter in place,&#148; <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148; or similar orders or restrictions or the closure of any physical branch
locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in the City of New York generally are open for use by customers on such Calendar Day. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Calendar Day</U></B>&#148; means each and every day of the week
(Sunday, Monday, Tuesday, Wednesday, Thursday, Friday and Saturday). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Commission</U></B>&#148; means the United
States Securities and Exchange Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Common Stock</U></B>&#148; means the common stock of the Company,
$0.0001 par value per share, and any other class of securities into which such securities may hereafter be reclassified or changed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Common Stock Equivalents</U></B>&#148; means any securities of the Company or the Subsidiaries which would entitle
the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Exchange Act</U></B>&#148; means the Securities Exchange
Act of 1934, as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Initial Exercise
Date</U></B>&#148; means May&nbsp;2, 2025. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Letter Agreement</U></B>&#148; means the Side Letter Agreement,
dated as of June&nbsp;17, 2025, among the Company and the signatories thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Person</U></B>&#148; means an
individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Purchase Agreement</U></B>&#148; means the Securities Purchase Agreement, dated as of March&nbsp;4, 2025, among the
Company and the purchasers signatory thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Securities Act</U></B>&#148; means the Securities Act of 1933,
as amended, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Series B Warrants</U></B>&#148; shall mean
the A&amp;R Series B Warrants as defined in the Letter Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Subsidiary</U></B>&#148; means any
subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Trading Day</U></B>&#148; means a Calendar Day on which the principal Trading Market is open for trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Trading Market</U></B>&#148; means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Transfer Agent</U></B>&#148; means Broadridge Corporate Issuer Solutions, Inc., the current transfer agent of the
Company, with a mailing address of 1155 Long Island Ave., Edgewood, NY 11717, and any successor transfer agent of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>VWAP</U></B>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
date) on OTCQB or OTCQX as applicable, (c)&nbsp;if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><U>Warrants</U></B>&#148; means this Warrant and other A&amp;R Series B Warrants as referenced in the Letter
Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exercise.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.1. <B><U>Exercise of Warrant</U></B>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto as Exhibit 2.1 (the &#147;<B><U>Notice of Exercise</U></B>&#148;). Within the earlier of (i)&nbsp;one (1) Trading Day and (ii)&nbsp;the
number of Trading Days comprising the Standard Settlement Period (as defined in Section&nbsp;2.4.1 herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the
applicable Notice of Exercise by wire transfer or cashier&#146;s check drawn on a United States bank unless the alternative cashless exercise procedure specified in Section&nbsp;2.3 below is specified in the applicable Notice of Exercise. No <FONT
STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days after the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by
acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.2. <B><U>Exercise</U></B><B><U> Price</U></B>. The exercise price per
Warrant Share shall be $1.98 , subject to adjustment hereunder (the &#147;<B><U>Exercise Price</U></B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.3. <B><U>Alternative
Cashless Exercise</U></B>. Whether or not an effective registration statement is available for the issuance of the Warrant Shares to the Holder, or the resale of the Warrant Shares by the Holder, the Holder may also effect an &#147;alternative
cashless exercise&#148;. In such event, the aggregate number of Warrant Shares issuable in such alternative cashless exercise pursuant to any given Notice of Exercise electing to effect an alternative cashless exercise shall equal the product of
(i)&nbsp;the aggregate number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise, multiplied by (ii) 1.0. Notwithstanding anything
herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via an alternative cashless exercise pursuant to this Section&nbsp;2.3. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section&nbsp;3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The
Company agrees not to take any position contrary to this Section&nbsp;2.3.&nbsp;[The parties acknowledge and agree that for purposes of&nbsp;Rule 144, the holding period of this Warrant tacks back to May&nbsp;9, 2024.]<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.4. <B><U>Mechanics of Exercise</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.1. <B><U>Delivery of Warrant Shares upon Exercise</U></B>. The Company shall cause the Warrant Shares purchased hereunder
to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system
(&#147;<B><U>DWAC</U></B>&#148;) if the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or
(B)&nbsp;the Warrant Shares are eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the
Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to
the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i)&nbsp;one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii)&nbsp;the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<B><U>Warrant Share Delivery Date</U></B>&#148;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
in the case of a cashless exercise) is received within the earlier of (i)&nbsp;two (2) Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. Notwithstanding
anything herein to the contrary, upon delivery of the Notice of Exercise, the Holder shall be deemed for purposes of Regulation SHO under the Exchange Act to have become the holder of the Warrant Shares irrespective of the date of delivery of the
Warrant Shares. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a
penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3rd) Trading Day after
the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a Transfer Agent that is a participant in the FAST
program so long as this Warrant remains outstanding and exercisable. As used herein, &#147;<B><U>Standard Settlement Period</U></B>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the
Initial Exercise Date, which may be delivered at any time after the time of execution of the Letter Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial Exercise Date
and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.2. <B><U>Delivery of New Warrants Upon Exercise</U></B>. If this Warrant shall have been exercised in part, the
Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant
Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.3.
<B><U>Rescission Rights</U></B>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2.4.1 by the Warrant Share Delivery Date, then the Holder will have the right to rescind such
exercise by delivering written notice to the Company at any time prior to the Company delivering such Warrant Shares. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Note to Draft: To be inserted for holders identified on Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> to
side letter. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.4. <B><U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT>
on Failure to Timely Deliver Warrant Shares upon Exercise</U></B>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the
provisions of Section&nbsp;2.4.1 above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any failure due solely to any action or inaction by the Holder with respect to such exercise),, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder was entitled to receive upon such exercise but did not receive (a &#147;<B><U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U></B>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the
Holder&#146;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to
deliver, but did not deliver, to the Holder in connection with the exercise at issue times (2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate
the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored and return any amount received by the Company in respect of the Exercise Price for those Warrant Shares (in which case such exercise shall be
deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock
having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under
clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.5. <B><U>No Fractional Shares or Scrip</U></B>. No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.6.
<B><U>Charges, Taxes and Expenses</U></B>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and
expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto as <U>Exhibit 2.4.6</U> duly executed by the Holder and the Company may require, as a
condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-Trading Day processing of any Notice of Exercise and all fees to the
Depository Trust Company (or another established clearing corporation performing similar functions) required for same-Trading Day electronic delivery of the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4.7. <B><U>Closing of Books</U></B>. The Company will not close its stockholder books or records in any manner which prevents
the timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">2.5. <B><U>Holder&#146;s Exercise Limitations</U></B>. The Company
shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after giving effect to such issuance after exercise as set
forth on the applicable Notice of Exercise, the Holder (together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s Affiliates (such Persons, &#147;<B><U>Attribution
Parties</U></B>&#148;), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number
of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, unexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or conversion of
the unexercised or unconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2.5, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section&nbsp;2.5 applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case
subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with
Section&nbsp;13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. For purposes of this Section&nbsp;2.5, in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the
Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading Day
confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#147;<B><U>Beneficial Ownership Limitation</U></B>&#148;
shall be [4.99%/9.99%] of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or
decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2.5, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2.5 shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until <FONT
STYLE="white-space:nowrap">sixty-one</FONT> (61)&nbsp;Calendar Days after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section&nbsp;2.5 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Certain Adjustments</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.1. <B><U>Stock Dividends and Splits</U></B>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock dividend or
otherwise makes a distribution or distributions on shares of Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by
the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of
shares, or (iv)&nbsp;issues by reclassification of shares of Common Stock any shares of capital stock of the Company, then in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of Shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3.1 shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or <FONT STYLE="white-space:nowrap">re-classification.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.2. <B><U>[RESERVED]</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.3. <B><U>Subsequent Rights Offerings</U></B>. In addition to any adjustments pursuant to Section&nbsp;3.1 above, if at any time the Company
grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all (or substantially all) of the record holders of any class of shares of Common Stock (the &#147;<B><U>Purchase
Rights</U></B>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the
extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or
beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.4. <B><U>Pro Rata Distributions</U></B>. During such time as this Warrant is
outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to all (or substantially all) holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&#147;<B><U>Distribution</U></B>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, that, to
the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would
not result in the Holder exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for
the benefit of the Holder until the Holder has exercised this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.5. <B><U>Fundamental Transaction</U></B>. If, at any time while
this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company or any Subsidiary, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one or more
related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or 50% or more of the voting power
of the common equity of the Company (each a &#147;<B><U>Fundamental Transaction</U></B>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2.5 on the exercise of this Warrant), the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<B><U>Alternate Consideration</U></B>&#148;) receivable as a result of such Fundamental Transaction by a holder of
the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2.5 on the exercise of this Warrant). For purposes of any such exercise,
the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#146;s option, exercisable at any time concurrently with, or within 30 Trading Days
after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black
Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&#146;s control,
including not approved by the Company&#146;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of
the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination
thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not
offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock/shares of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in
such Fundamental Transaction. &#147;<U>Black Scholes Value</U>&#148; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg, L.P. (&#147;<B><U>Bloomberg</U></B>&#148;)
determined as of the Trading Day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date
of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to 100, (C) the underlying price per share used in such calculation shall be the sum of the price per
share being offered in cash, if any, plus the value of any <FONT STYLE="white-space:nowrap">non-cash</FONT> consideration, if any, being offered in such Fundamental Transaction, (D)&nbsp;a remaining option time equal to the time between the date of
the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such
other consideration) within the later of (i)&nbsp;five (5) Business Days after the Holder&#146;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &#147;<B><U>Successor Entity</U></B>&#148;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of this Section&nbsp;3.5 pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant that
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations
on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
prior to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#147;Company&#148;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant referring to the &#147;Company&#148; shall refer instead to each of the Company and the Successor
Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the
avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section&nbsp;3.5 regardless of (i)&nbsp;whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or
(ii)&nbsp;whether a Fundamental Transaction occurs prior to the Initial Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.6.<B> </B><B><U>Calculations</U></B>. All
calculations under this Section&nbsp;3 shall be made to the nearest fraction of a cent as in the initial Exercise Price or the nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock
deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.7. <B><U>Notice to Holder</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7.1. <B><U>Adjustment to Exercise Price</U></B>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7.2. <B><U>Notice to Allow Exercise by Holder</U></B>. If (A)&nbsp;the Company shall declare
a dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email
to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 Calendar Days prior to the applicable record or effective date hereinafter specified, a notice stating (x)&nbsp;the date on which a
record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that
the failure to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice
provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.8. <B><U>[RESERVED]</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.9. <B><U>Voluntary</U></B><B><U> Adjustment </U></B><B><U>by</U></B><B><U> Company</U></B>. The Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company; provided, however, that the Company agrees not to adjust the Exercise Price in any way that
would violate the listing rules of the Nasdaq Stock Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.10. <B><U>[RESERVED]</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3.11. <B><U>[RESERVED]</U></B>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Transfer of Warrant</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.1. <B><U>Transferability</U></B>. Subject to the Holder&#146;s appropriate compliance with the restrictive legend on this Warrant and the
transfer restrictions set forth herein and in the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto as <U>Exhibit 2.4.6</U> duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in
the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within
three (3)&nbsp;Trading Days after the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.2. <B><U>New Warrants</U></B>. Subject to compliance with applicable securities
laws, this Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section&nbsp;4.1, as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the
Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial Issuance Date of this Warrant and shall be identical with this Warrant except as to the number of
Warrant Shares issuable pursuant thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.3. <B><U>Warrant Register</U></B>. The Company shall register this Warrant, upon records to be
maintained by the Company for that purpose (the &#147;<B><U>Warrant Register</U></B>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.4 <B><U>Transfer Restrictions</U></B>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the
transfer of this Warrant shall not be either (i)&nbsp;registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder
or transferee of this Warrant, as the case may be, comply with the provisions of Section&nbsp;4.1(c) of the Purchase Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">4.5 <B><U>Representation by the Holder</U></B>. The Holder, by the acceptance hereof,
represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or
any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>Miscellaneous</U></B>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.1. <B><U>No Rights as Stockholder until Exercise; No Settlement in Cash</U></B>. This Warrant does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2.4.1, except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant Shares on
an &#147;alternative cashless exercise&#148; pursuant to Section&nbsp;2.3 or to receive cash payments pursuant to Section&nbsp;2.4.1 and Section&nbsp;2.4.4 herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant. For the avoidance of doubt, except as expressly set forth in this&nbsp;Warrant, in no event does this agreement result in the Company having an obligation to issue cash or other assets to the Holder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.2. <B><U>Loss, Theft, Destruction or Mutilation of Warrant</U></B>. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it
(which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like
tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.3. <B><U>Saturdays, Sundays, Holidays,
etc</U></B>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action may be taken, or such right may be exercised, on the next succeeding
Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.4. <B><U>Authorized Shares</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4.1. <B><U>Reservation of Authorized and Unissued Shares</U></B>. The Company covenants that, during the period commencing on
the Initial Exercise Date through the Termination Date, it will reserve from its authorized and unissued Common Stock a sufficient number of shares of Common Stock to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights
under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading
Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this
Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable (which means that no further sums are required to be paid by the holders thereof in connection with the issue
thereof) and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4.2. <B><U>Noncircumvention</U></B>. Except and to the extent as waived or consented to by the Holder, the Company shall not
by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek
to avoid the observance or performance of any of the terms of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of
Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately
prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and
(iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this
Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4.3. <B><U>Authorizations, Exemptions and Consents</U></B>. Before taking any action that would result in an
adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4.4. <B><U>Information Rights</U></B>. For so long as the Warrant remains
outstanding, the Company shall, at the close of each Trading Day calculate the total number of shares of Common Stock of the Company then outstanding, and deliver such calculation in writing to the Holder.&nbsp;Such calculation shall reflect the
number of shares of Common Stock outstanding as of the close of trading on that Trading Day and shall be delivered by electronic mail or other agreed-upon means. Holder shall be entitled to rely on such calculation for purposes of determining the
applicability of the Beneficial Ownership Limitation (as defined above). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.5. <B><U>Governing Law</U></B>. All questions concerning the
construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each
party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
stockholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in
any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in
effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other
manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable
attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Notwithstanding the foregoing, nothing in this paragraph shall limit or restrict the federal district court
in which a Holder may bring a claim under the federal securities laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.6. <B><U>Restrictions</U></B>. The Holder acknowledges that the
Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.7. <B><U>Nonwaiver and Expenses</U></B>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies. Without limiting any other provision of this Warrant, the Purchase Agreement or the Letter Agreement, if the Company willfully and knowingly
fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to,
reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.8. <B><U>Notices</U></B>. Any and all notices or other communications or deliveries to be
provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or sent by a nationally recognized overnight courier service,
addressed to the Company, at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756, Attention: Andrew Sims, Chief Financial Officer, email address: asims@plustherapeutics.com, or such other email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by <FONT STYLE="white-space:nowrap">e-mail,</FONT> or sent by a
nationally recognized overnight courier service addressed to each Holder at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries
hereunder shall be deemed given and effective on the earliest of (i)&nbsp;the time of transmission, if such notice or communication is delivered via <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT>
address set forth in this Section&nbsp;5.8 prior to 5:30 p.m. (New York City time) on any date, (ii)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via
<FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth in this Section&nbsp;5.8 on a Calendar Day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading
Day, (iii)&nbsp;the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv)&nbsp;upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to
a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.9. <B><U>Limitation of Liability</U></B>. No provision hereof, in
the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.10. <B><U>Remedies</U></B>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby
agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.11.
<B><U>Successors and Assigns</U></B>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the
successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.12. <B><U>Amendment</U></B>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company,
on the one hand, and a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of Holders of the Series B Warrants, on the other hand. No modification or amendment or modification of the provisions hereof
may be waived in a manner that is more favorable to other holder(s) of Series B Warrants, as applicable, or to treat any holder(s) of Series B Warrants in a manner that is in any respect not equal to the treatment of all other holder(s) of Series B
Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.13. <B><U>Severability</U></B>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">5.14. <B><U>Headings</U></B>. The headings used in this Warrant
are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">******************** </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Plus Therapeutics Investor Series B Common Warrant Signature Page Follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Plus Therapeutics, Inc. Investor Series B Common Warrant Signature Page] </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Series B Common Warrant to be executed by its officer thereunto duly authorized as of the date
first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>PLUS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 2.1 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plus Therapeutics, Inc. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)
Payment shall take the form of (check applicable box): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in lawful money of the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the cancellation of such number of Warrant Shares as is necessary, in accordance with the provisions of
subsection 2.3, to exercise this Warrant pursuant to the &#147;alternative cashless exercise&#148; procedure set forth in subsection 2.3. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Plus Therapeutics, Inc. Investor Series B Common Warrant Exercise Notice &#150; Investor
Signature Page] </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Investing Entity: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Signature
of Authorized Signatory of Investing Entity: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name of Authorized Signatory: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of Authorized Signatory: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Exhibit 2.4.6 </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ASSIGNMENT FORM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares of Common Stock.) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone Number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email Address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder&#146;s Signature: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holder&#146;s Address: </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d942989dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">June&nbsp;17, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Plus Therapeutics, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4200 Marathon Blvd., Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Austin, Texas 78756 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: Letter Agreement (this &#147;<U>Agreement</U>&#148;) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to that
certain Securities Purchase Agreement, dated as of March&nbsp;4, 2025 (the &#147;<U>Purchase Agreement</U>&#148;), by and among Plus Therapeutics, Inc. (the &#147;<U>Company</U>&#148;) and each of the other parties party thereto (each, an
&#147;<U>Investor</U>&#148; and collectively, the &#147;<U>Investors</U>&#148;). Capitalized terms used but not defined in this letter agreement (this &#147;<U>Agreement</U>&#148;) shall have the meanings ascribed to them in the Purchase Agreement.
Pursuant to the Purchase Agreement, the Company sold to the Investors, in a private placement (the &#147;<U>Private Placement</U>&#148;), an aggregate of 28,042,140 shares (the &#147;<U>Private Placement Shares</U>&#148;) of the Company&#146;s
common stock, par value $0.001 per share (&#147;<U>Common Stock</U>&#148;) (or <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#148;) to purchase shares of
Common Stock (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Shares</U>&#148;) in lieu thereof), 28,042,140 Series A common warrants (the &#147;<U>Series A Warrants</U>&#148;) to purchase shares of Common Stock (the
&#147;<U>Series A Warrant Shares</U>&#148;), and 28,042,140 Series B common warrants (the &#147;<U>Series B Warrants</U>&#148;) to purchase shares of Common Stock (the &#147;<U>Series B Warrant Shares</U>&#148;). In connection with the Purchase
Agreement, on March&nbsp;4, 2025, the Company entered into the Registration Rights Agreement with the Investors, pursuant to which the Investors were granted certain registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;5.5 of the Purchase Agreement, the Purchase Agreement may be amended by the Company and Purchasers who purchased at
least 67% in interest of the Private Placement Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants based on the initial Subscription Amounts thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;5.12 of the Series A Warrants, each Series A Warrant may be amended by the Company and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;majority-in-interest&nbsp;of</FONT></FONT> holders of the Series A Warrants issued pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;5.12 of the Series B Warrants, each Series B Warrant may be amended by the Company and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;majority-in-interest&nbsp;of</FONT></FONT> holders of the Series B Warrants issued pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;6(d) of the Registration Rights Agreement, the Registration Rights Agreement may be amended by the Company and
holders of 50.1% or more of the then outstanding Registrable Securities (as defined in the Registration Rights Agreement). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
consideration of the mutual covenants contained in this Agreement, and for good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the undersigned Investors and the Company hereby agree as follows:</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Amendment of the Purchase Agreement; Termination of Registration Rights Agreement</U>. Effective as of the date hereof,
Section&nbsp;4.11 (under the heading &#147;Subsequent Equity Sales&#148;) of the Purchase Agreement shall be removed in its entirety. Effective as of the date hereof, the Registration Rights Agreement shall be terminated in full and rendered null
and void, and all past, current, or future obligations of the Company under the Registration Rights Agreement shall be extinguished. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Cancellation of Series A Warrants</U>. Effective as of the date hereof, all Series A
Warrants shall be terminated in full and rendered null and void, and all past, current, or future obligations of the Company under the Series A Warrants shall be extinguished. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Issuance of A&amp;R Series B Warrants</U>. Effective as of the date hereof, (i)&nbsp;all Series B Warrants held by the Investors listed
on <U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT></U> hereto shall exchanged, pursuant to Section&nbsp;3(a)(9) of the Securities Act, for warrants in the form of <U>Exhibit B</U> hereto (each, an &#147;<U>A&amp;R Series B Warrant</U>&#148;),
with each such A&amp;R Series B Warrant exercisable for a number of shares of Common Stock set forth opposite the name of the applicable Investor on <U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT></U>, and (ii)&nbsp;all Series B Warrants held
by the Investors listed on <U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></U> hereto shall be exchanged, pursuant to Section&nbsp;3(a)(9) of the Securities Act, for warrants in the form of the A&amp;R Series B Warrant, with each such A&amp;R
Series B Warrant exercisable for a number of shares of Common Stock set forth opposite the name of the applicable Investor on <U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT></U> hereto. Each A&amp;R Series B Warrant will have an alternative
cashless exercise feature with a ratio of 1:1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Return of Private Placement Shares and
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>. Within five (5)&nbsp;business days of the Company&#146;s written request, each of the undersigned Investors agrees to return any Private Placement Shares and <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants held by it as of the date hereof to the Company. Any Private Placement Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants not so returned by an Investor shall reduce the
Make-Whole Amount (as defined below) applicable to such Investor by a value of $0.66 per Private Placement Share and $0.659 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Subsequent Financings</U>. When the Company shall raise any capital on or subsequent to July&nbsp;1, 2025, whether through a subsequent
financing transaction, asset sale, sale of equity or debt securities or otherwise (each, a &#147;<U>Subsequent Financing</U>&#148;), the Company shall remit 90% of the proceeds received therefrom (after deducting offering expenses and underwriting
discounts and commissions or placement agent fees) to the Investors, until each Investor has received cash equal to 115% of such Investor&#146;s Make-Whole Amount (the &#147;<U>Maximum Amount</U>&#148;). As used herein, &#147;<U>Make-Whole
Amount</U>&#148; means, with respect to an Investor, the amount equal to (a)&nbsp;such Investor&#146;s Subscription Amount as set forth on its signature page to the Purchase Agreement, <I>minus</I> (b)&nbsp;the aggregate amount of gross cash
proceeds (the &#147;<U>Resale Amount</U>&#148;) the Investor has received as of the date of this Agreement from selling any securities received pursuant to the Purchase Agreement or from selling any securities received upon exercise of any
securities received pursuant to the Purchase Agreement, in each case, to any third-party. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Manner of Payments</U>. Payments made to any Investor pursuant to this Section&nbsp;5 shall be made on the
15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> and 28<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> of each calendar month, pro rata in proportion to such Investor&#146;s Make-Whole Amount, relative to the sum of all Make-Whole
Amounts for all Investors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Investor Acknowledgement</U>. Each Investor acknowledges and understands that the Company is obligated to
meet Nasdaq&#146;s continued listing criteria, including requirements regarding maintenance of stockholders&#146; equity thresholds. Accordingly, while the Company agrees to use commercially reasonable efforts to ensure that each Investor receives
its Maximum Amount, each Investor further acknowledges and agrees that, notwithstanding the foregoing, the Company shall become obligated to remit proceeds to such Investor only when a Subsequent Financing is consummated. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Representations and Warranties</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached
hereto. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Investor represents and warrants that (i)&nbsp;it is the sole owner and holder of the Private Placement
Shares and <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants set forth on its signature page of the Purchase Agreement, and has not assigned, transferred, sold, pledged, conveyed or otherwise disposed of (or attempted any of the foregoing
with respect to) such securities, (ii)&nbsp;has the power and authority to execute and deliver this Agreement, (iii)&nbsp;the calculation of its Make-Whole Amount set forth on its signature page to this Agreement is true and correct; and
(iv)&nbsp;the calculation of the number of Series B Warrant Shares underlying the Series B Warrant held by it as of date hereof, as set forth on Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> hereto, is true and correct. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Public Disclosure</U>. On or before 9:30 a.m. Eastern Time on the business day immediately after the date
hereof, the Company will file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the U.S. Securities and Exchange Commission disclosing all material terms of the transactions contemplated hereunder. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Rights</U>. Nothing contained in this Agreement, and no action taken by any Investor pursuant
hereto, shall be deemed to constitute such Investor and the other parties hereto as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that any Investor and the other parties hereto are in any way
acting in concert or as a group with respect to the transactions contemplated by this Agreement and the Company acknowledges that any Investor and the other parties hereto are not acting in concert or as a group with respect to the transactions
contemplated by this Agreement or any other agreement with the same terms as this Agreement. The Company and each Investor confirms that such Investor has independently participated in the negotiation of the transactions contemplated hereby with the
advice of such Investor&#146;s own counsel and advisors. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any
other party hereto to be joined as an additional party in any proceeding for such purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Equal Treatment</U>. By executing this Agreement, each undersigned Investor and the Company agree that the
terms of this Agreement do not violate Sections 4.12 and 5.5 of the Purchase Agreement, Section&nbsp;5.12 of the Series A Warrant and Section&nbsp;5.12 of the Series B Warrant. Each undersigned Investor and the Company agree not to take any position
to the contrary. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Release</U>. Each party hereto agrees to release and discharge each other party hereto, severally and not
jointly, from any and all claims, potential claims, demands or causes of action, judgements, liabilities or other obligations, whether known or unknown, existing, contingent or otherwise, suspected or unsuspected, asserted or unasserted, that each
such party has, had or may have against each such other party, (i)&nbsp;arising from the date of the Purchase Agreement through the date of this Agreement, in connection with any exercise of the Series B Warrants and the delivery of Series B Warrant
Shares; or (ii)&nbsp;arising from fulfillment of the transactions contemplated hereby. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Injunctive Relief</U>. The parties acknowledge and agree that any failure by the Company to timely deliver
shares of Common Stock upon exercise of any such A&amp;R Series B Warrant in accordance with its terms described in section 2.4.1 will result in irreparable harm to the applicable holder of such A&amp;R Series B Warrant for which there may be no
adequate remedy at law. Accordingly, in the event of any such failure, each holder of any such A&amp;R Series B Warrant shall be entitled to seek specific performance and injunctive or other equitable relief to enforce the delivery of such shares,
in addition to any other rights or remedies available to such holder at law or in equity. The Company hereby waives, and agrees not to assert, any defense that a remedy at law would be adequate in any such action for specific performance or
injunctive relief. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>General</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as set forth herein or as contemplated hereby, there are no amendments, modifications or waivers to the
Purchase Agreement, Series A Warrants, Series B Warrants, <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants or Registration Rights Agreement. Except as modified by this Agreement, all rights previously available to holders of the Series B
Warrants shall remain in full force and effect. Notwithstanding anything herein to the contrary, each undersigned Investor hereby agrees that any shares of Common Stock delivered pursuant to a notice of exercise by such Investor under its Series B
Warrant prior to the date hereof were delivered timely and otherwise in compliance with the terms of the Series B Warrant and the Purchase Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement contains and comprises the entire agreement and understanding between the parties with respect
to the subject matter hereof and supersedes all previous covenants and agreements of any kind between the parties with respect to such subject matter. The terms of this Agreement shall not be amended or changed except in writing and signed by a duly
authorized representative of each party. This Agreement shall be binding on and inure to the benefit of each party, their successors and assigns. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any shares of Common Stock issued pursuant to exercise of the Series B Warrants as of the date hereof are not
subject to forfeiture. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement shall be governed by and construed in accordance with the domestic laws of the State of New York
without giving effect to any choice or conflict of law provisions or rule (whether of the State of New York or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart. In the event that any
signature is delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery of a &#147;.pdf&#148; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such &#147;.pdf&#148; signature page were an original thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature
Pages Follow] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">INVESTOR:</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">______________________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Calculation of the Investor&#146;s Make-Whole Amount (defined in Section&nbsp;5 of the Agreement) </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As set forth on the Investor&#146;s signature page to the Purchase Agreement, the Purchaser&#146;s Subscription
Amount is $_______________________________. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As demonstrated by brokerage statements or documentation reasonably acceptable to the Company, the
Investor&#146;s Resale Amount is $__________________________. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">(a)&#8201;&#150;&#8201;(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Investor&#146;s Make-Whole Amount is $___________________________. </B> </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>&#8195;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>In lieu of disclosing the Investor&#146;s Resale Amount and Make-Whole Amount, Investor may instead check
the following box affirming that the Make-Whole Amount is $0.00 </B>&#9745;<B></B><B> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>ETTER</SMALL> A<SMALL>GREEMENT</SMALL> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acknowledged and accepted:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PLUS THERAPEUTICS, INC.&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">__________________________________________</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> L<SMALL>ETTER</SMALL> A<SMALL>GREEMENT</SMALL>
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Annex A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby makes the following representations and warranties to each Investor: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions
contemplated hereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in connection therewith. This Agreement has been duly
executed by the Company and, when delivered in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i)&nbsp;as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally; (ii)&nbsp;as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies; and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>No Conflicts</U>. The execution, delivery and performance of this Agreement by the Company and the consummation by the
Company of the transactions contemplated hereby do not and will not: (i)&nbsp;conflict with or violate any provision of the Company&#146;s certificate of incorporation, as amended, bylaws or other organizational or charter documents; or
(ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims, security interests, other encumbrances or defects upon any of the
properties or assets of the Company in connection with, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other
material instrument (evidencing Company debt or otherwise) or other material understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii)&nbsp;conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and state securities laws and regulations and Nasdaq rules and
regulations), or by which any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii)&nbsp;and (iii), such as could not have or reasonably be expected to result in a material adverse effect upon the
business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Filings, Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order
of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of this Agreement,
other than the filings required pursuant to this Agreement. No additional listing application is required to be filed with Nasdaq in connection with the transactions contemplated by this Agreement, nor do Nasdaq rules require that shareholder
approval be obtained to enter into and fulfill the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Rule 144</U>. To the Company&#146;s
knowledge, the transactions contemplated by this Agreement do not negatively impact any investor&#146;s right to &#147;tack&#148; back to a prior holding period
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Series B Warrants for purposes of compliance with Rule 144 of the Securities Act of 1933, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT> </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> </U></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit B </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of A&amp;R Series B Warrant </U></B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pstv-20250617.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/18/2025 12:17:11 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:pstv="http://www.plustherapeutics.com/20250617"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.plustherapeutics.com/20250617"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20250617_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pstv-20250617_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>pstv-20250617_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/18/2025 12:17:11 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>pstv-20250617_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 6/18/2025 12:17:11 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="pstv-20250617.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001095981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0827593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2710 Reed Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(737)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-7194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PSTV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d942989d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d942989d8k.htm">d942989d8k.htm</File>
    <File>pstv-20250617.xsd</File>
    <File>pstv-20250617_lab.xml</File>
    <File>pstv-20250617_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d942989d8k.htm": {
   "nsprefix": "pstv",
   "nsuri": "http://www.plustherapeutics.com/20250617",
   "dts": {
    "inline": {
     "local": [
      "d942989d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "pstv-20250617.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "pstv-20250617_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pstv-20250617_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-06-17_to_2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942989d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-06-17_to_2025-06-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d942989d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.plustherapeutics.com//20250617/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-142093-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-142093-xbrl.zip
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M5;H&$2T0USR]*R@V5A7=705:54R'A)"3?NA-VB<>OR5237SVKN!Q&?ET@CK
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M(J=WWOGMJGO=/>^1TXLS<OY'Y^/IQ2_GI//E\^=NK]?]<O$H&IU=T/@[E4-
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MNC:<6I3PC?N*7:,EVTFWEJDRS*0'I*JPL3>G9I5-CP<Y]/FJ-4^N-9>"X<Z
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M3A8)&%8 1N[0Z&O-W.<KDDL_EN0Z]PJ@(ND&;IGLHSG$]7*LXTZV.3J.?7Q
MM,YH6 (L4$.J0-B$HH!2<@#A,H;!J,QQHTCPQJ&WA(R9T18;I@,GR5I8]Y8*
MG"*:=5U92(3K2B<(" 9D+>M1R&E/^?W N$#8()DI(#,9)WD(,11-.T H!E(>
M"7Z+.U_D4Q/2FQE/3]!,[#*I>)E6S)@XFY0@IXQ+MJ*$E!;9YP>&63 NO0&>
MW"272&M%ZZA9K%<;1 ZI@)8S<YX?F/1TI6S\V6&R3";7N$!RN0N$>[,9;5Y
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M%X.*;1#/2<7\[JG^2=3V_P-02P,$%     @ *(/16NR'R8D5'0  D94  !$
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MH6A%$R43G8P J_(PTP.<&(]337@6U7""G78+OLQ+"3/RPXW'C-\;6(L\C>W
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MFHJ 08/E("_G8N[&6E(7AF0=# QXC3Y6+6<UD!J-GERI3P+YK![J$--TL0J
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MC^+IPU%\DZ,XO)5;_O;K>&-N@5[:1FKU^<.O'U[_ 5^^Z[\_WO]_4$L#!!0
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MJ$LMQX3V6];4\AJXM# D+:0R9\,;'>\X#6WV3$["299_C-[-X1LY"[C,)*I
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MBF>%!_2GX$H 5![0/H"!ADG^L=)AB ,#X0U+QEM5@F$!NT)G#<PS')VG>E$
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M_@@X8(:WL@=/[".9O"H(1AKQ0RX(0)76_1[UC-3@_,HT'R]/;*LN+K@(SOA
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M4+\34/,?CW:>//G+#T_P?_^IC.TF9],+:*_8$"]"\3E6J1OKEG!R:V9S3%Q
MZL%2JD.GT*QFS*]SJ+0 A34Y;;/UZ[IA,YRN!"DT 8FH_P6)S_&.-=1?[0JX
M3*==08<-"*5P$ 5*8^E@"SKX<B?:SYT]$F5U'0F-XWF8.M &7%2W05)"E7VJ
ME_>!%1J,V!^5);H]62HW25$S)E9A')ZWT\*@RSD&94'-!"5'*<.$FAFC]E)
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M[]3:G,Z\R._C0.JY\;B' VX>OGPU4]DZM,?$Z!9B\-/NKM]O(\N^PGXSR,W
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M_344Q#/-W(Z59@=TQNJQCA_P&Q?BH[1\&!J>2LJ!)27N]X'0T@K1E](CF;F
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MY\F^BWT"B&J'16J%08I:4)#4C:C%G^B!=E*(;$]$"=D(I%DN;C/2?[FK$S-
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MOP6W&MN ZV7;'7G';#.NO>T*UXTS6Y_G]J8_]\U5LW?HYT]02P,$%     @
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M+FAT;5!+ 0(4 Q0    ( "B#T5KY&B<)GTX  &YK 0 0              "
M :LP  !D.30R.3@Y9&5X-#$N:'1M4$L! A0#%     @ *(/16K:K1HM$ P
M90L  !$              ( !>'\  '!S='8M,C R-3 V,3<N>'-D4$L! A0#
M%     @ *(/16H12@\^ !@  ND8  !4              ( !ZX(  '!S='8M
M,C R-3 V,3=?;&%B+GAM;%!+ 0(4 Q0    ( "B#T5J-YD?LS@0  % L   5
M              "  9Z)  !P<W1V+3(P,C4P-C$W7W!R92YX;6Q02P4&
/  8 !@!^ 0  GXX

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d942989d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pstv-20250617.xsd" xlink:type="simple"/>
    <context id="duration_2025-06-17_to_2025-06-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001095981</identifier>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-06-17_to_2025-06-17"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-278">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-06-17_to_2025-06-17"
      id="Hidden_dei_EntityCentralIndexKey">0001095981</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-289">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-290">2025-06-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-291">PLUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-292">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-293">001-34375</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-294">33-0827593</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-295">2710 Reed Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-296">Suite 160</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-297">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-298">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-299">77051</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-300">(737)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-301">255-7194</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-302">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-303">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-304">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-305">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-306">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-307">PSTV</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-06-17_to_2025-06-17" id="ixv-308">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
